{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Investigating the New Strategies in Glycemic Management – OAD and Injectable Therapy Survey (INSIGHT)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. What proportion of new patients presenting to you have uncontrolled T2DM? *

  2. Which factor do you consider most critical in managing diabetes among Indian patients? *

  3. Which oral antidiabetic drug do you most commonly prescribe to Indian patients? *

  4. How often do you recommend lifestyle modifications (diet and exercise) to your Indian patients with diabetes? *

  5. What is the most common barrier to effective diabetes management among your Indian patients?*

  6. Which complication of diabetes do you find most prevalent among your Indian patients? *

  7. What is the proportion of patients taking only oral antidiabetic drugs? *

  8. What is the proportion of patients taking only injectable drugs? *

  9. What proportion of patients are on both oral antidiabetic drugs and injectable drugs? *

  10. What according to you is the typical duration after which “OAD failure” can be considered in a patient who has uncontrolled T2DM on OADs? *

  11. What are the proportion of your patients are on: *
    		12.
  12. What is the typical duration of diabetes in patients who are initiated on insulin? *

  13. What are the proportion of patients who get adequate control on basal insulins + OADs? *

  14. What factors do you consider most important when deciding between insulin and oral antidiabetic therapy for a patient? (Please specify) *
  15. How often do you encounter patients who are hesitant to start insulin therapy? *

  16. What are the common barriers you observe in patients when initiating insulin therapy? (Please specify) *
  17. What challenges do you anticipate in incorporating insulin therapy into your patients daily life? *

  18. What factors would make you more comfortable with starting insulin therapy? (Please specify) *
  19. What are the most common concerns or misconceptions patients have about starting insulin therapy? (Please specify) *
  20. Can you share any strategies or approaches that have been effective in overcoming barriers to insulin initiation? (Please specify) *
  21. What criteria do you use to determine when to prescribe oral antidiabetic drugs in combination with insulin? *
  22. What challenges do you encounter when managing patients on combination therapy, and how do you address them? *
  23. According to you which class of oral antidiabetic drugs should be preferred in patients on insulin? (Please specify) *
  24. What factors do you consider when deciding to reduce a patient's insulin dose in favour of oral antidiabetic drugs? (Please specify) *
  25. How often do you encounter patients who are candidates for reducing insulin doses with oral antidiabetic drugs? (Please specify) *
  26. Do you believe that patients on Sitagliptin + Metformin require lower doses of insulin when compared to patients taking insulin alone? (Please specify) *
  27. By what percentage are you able to reduce insulin doses with DPP4i+Metformin? *

  28. What are the most common oral antidiabetic drugs you prescribe when reducing insulin doses? (Please specify) *
  29. How frequently do you monitor patients after reducing their insulin dose and starting oral antidiabetic drugs? *

  30. What is the most common challenge you face when transitioning patients from insulin to oral antidiabetic drugs?*

  31. Which combination do you find most effective in reducing HbA1c levels in patients on insulin? *

  32. Which combination is associated with the least risk of hypoglycemia in patients on insulin? *

  33. Which combination do you find most effective in promoting weight loss in patients on insulin? *

  34. Which combination has the best patient adherence in your experience? *

  35. Which combination do you find most cost-effective for patients on insulin? *

  36. Which combination do you find most effective in reducing fasting blood glucose levels in patients on insulin? *

  37. Which combination do you find most effective in reducing postprandial blood glucose levels in patients on insulin? *

  38. What are the key benefits you observe when prescribing the sitagliptin + metformin combination compared to other oral antidiabetic drugs? *
  39. How do patient outcomes with sitagliptin + metformin vary as compared to those with other oral antidiabetic therapies in your experience? *
  40. What factors influence your decision to prescribe GLP-1 receptor agonists (GLP-1RAs) for a patient with Type 2 Diabetes? (Select all that apply) *

  41. What according to you is the durability of HBA1c control with the background of insulin therapy in patients of T2DM? *

  42. What are the most common side effects that you observe in your patients when using GLP- 1 receptor agonists? *

  43. How confident are you in the long-term safety of using GLP-1 agonists in your patients with Type 2 Diabetes? *

  44. When treating a patient with Type 2 Diabetes and Obesity, which combination of therapies do you typically consider? *

  45. For patients with Type 2 Diabetes and established Atherosclerotic Cardiovascular Disease (ASCVD), how frequently do you prescribe GLP-1 receptor agonists alongside other antidiabetic drugs? *

  46. In patients with Type 2 Diabetes and Metabolic Associated Fatty Liver Disease (MASLD), which combination of therapies do you most commonly prescribe? *

  47. For patients with Type 2 Diabetes and Heart Failure, how do you approach the combination of antidiabetic drugs and GLP-1 receptor agonists? *

  48. In patients with Type 2 Diabetes and Chronic Kidney Disease (CKD), how often do you use GLP-1 receptor agonists in combination with conventional antidiabetic medications? *

  49. How often do you observe improvement in time in range if patients on insulin are initiated on DPP4i? *

  50. What proportion of uncontrolled patients in your opinion achieve target HBA1c goals when started on the combination of DPP4i and Metformin?(Please specify) *
  51. How would you describe your experience with the integration of newer insulin delivery systems in the management of diabetes compared to traditional methods? *
  52. What are your views on the impact of advanced insulin delivery systems on reducing the risk of hypoglycemia? *
  53. In which patient population is the use of CGM most commonly recommended? *

  54. What is a key advantage of using CGM over traditional fingerstick blood glucose testing? *

  55. What is one potential limitation of using CGM in routine clinical practice? *

  56. What do you consider to be the most significant challenge in the clinical implementation of pancreatic beta-cell transplantation for diabetes treatment? *